Entrada Therapeutics Inc (TRDA) - News Archive

In a significant advancement for the treatment of Duchenne Muscular Dystrophy (DMD), Entrada Therapeutics has received authorization from the United Kingdom s regulatory authorities to initiate the ELEVATE-45-201 study....

Duchenne muscular dystrophy (DMD) represents one of the most challenging and devastating genetic disorders, characterized by progressive muscle degeneration and weakness. It primarily affects boys and leads to severe fu...

Entrada Therapeutics, a leading biotechnology company, announced its successful completion of a $100 million registered direct offering. The round was championed by a U.S.-based healthcare-focused investor, two global m...

Entrada Therapeutics has recently announced the successful completion of preliminary data analysis from their Phase 1 clinical trial ENTR-601-44-101 involving the investigation of ENTR-601-44 in healthy volunteers for t...

In its ongoing efforts to combat Duchenne Muscular Dystrophy (DMD), Entrada Therapeutics Inc has achieved significant milestones by completing the dosing of the first and second cohorts in its Phase 1 clinical trial for...